Sana Biotechnology Reports First Quarter 2021 Financial Results and Business Updates
May 05, 2021 16:05 ET
|
Sana Biotechnology, Inc
Presented key proof of concept data for multiple platforms at AACR 2021 Q1 2021 cash position of $981.9 million SEATTLE, May 05, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a...
Sana Biotechnology to Present at the BofA Securities 2021 Healthcare Conference
May 04, 2021 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, May 04, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...
Sana Biotechnology to Present Pre-Clinical Data at American Society of Gene & Cell Therapy Annual Meeting 2021
April 27, 2021 16:35 ET
|
Sana Biotechnology, Inc
— Fusogen platform demonstrates potential for cell-specific in vivo delivery of gene therapies to multiple cell types, including T cells and hepatocytes — SEATTLE, April 27, 2021 (GLOBE NEWSWIRE)...
Sana Biotechnology Reports Fourth Quarter and 2020 Financial Results and Business Updates
March 24, 2021 16:10 ET
|
Sana Biotechnology, Inc
Expects to present data at multiple scientific conferences in 2021 2020 year-end cash position of $412 million Further strengthened cash position with $627 million in net IPO proceeds SEATTLE,...
Sana Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 08, 2021 17:24 ET
|
Sana Biotechnology, Inc
SEATTLE, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the closing of its...
Sana Announces Upsized Pricing of Initial Public Offering
February 03, 2021 23:22 ET
|
Sana Biotechnology, Inc
SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Sana) (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the pricing of...